<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02706678</url>
  </required_header>
  <id_info>
    <org_study_id>BJ309CT-02</org_study_id>
    <nct_id>NCT02706678</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients</brief_title>
  <official_title>Efficacy and Safety of a Post-transplantation Switch From Cyclosporin to Tacrolimus Sustained-release Capsules in Renal Transplant Recipients: A Multi-center, Open-label, Uncontrolled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma China, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effects of tacrolimus sustained-release
      capsules replacing cyclosporin on kidney function of renal transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in creatinine level</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in creatinine level</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rejection reaction after drug use</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of tacrolimus</measure>
    <time_frame>Weeks 1, 2, 4, 8, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 8, 12 and 24</time_frame>
    <description>Diastolic pressure and systolic pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood lipid</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 8, 12 and 24</time_frame>
    <description>Total cholesterol, high density lipoprotein, low density lipoprotein, triglyceride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in liver function</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 8, 12 and 24</time_frame>
    <description>Aspartate aminotransferase, alanine aminotransferase, bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting blood glucose</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 8, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in gingival hyperplasia</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in polytrichia</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Adverse Events</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Renal Transplant Recipients</condition>
  <arm_group>
    <arm_group_label>Tacrolimus sustained-release capsule group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus sustained-release capsule</intervention_name>
    <description>Oral</description>
    <arm_group_label>Tacrolimus sustained-release capsule group</arm_group_label>
    <other_name>FK506</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years of age, male or female

          -  1-5 years after kidney transplantation

          -  The patient has been accepting cyclosporin-based immunosuppressive therapy for ≥6
             months, and the therapeutic regimen has kept stable for at least 4 weeks before
             inclusion

          -  The dose of cyclosporin has kept stable for at least 4 weeks before inclusion

          -  At least one of the cyclosporin-related adverse reactions is present or the answer to
             the 5th question in the questionnaire is &quot;Yes&quot; at the time of inclusion:

          -  gingival hyperplasia and treatment requested by the patient

          -  polytrichia and interventional therapy requested by the patient

          -  post-transplantation hypertension

          -  post-transplantation hyperlipemia (total cholesterol&gt;5.7 mmol/L (220 mg/dl))

          -  Serum creatinine&lt;200 μmol/l ( 2.3 mg/dl)

          -  A promise is made to take contraceptive measures during the study (women at
             childbearing ages).

        Exclusion Criteria:

          -  Patients having accepted transplantation of other organs apart from kidney
             transplantation

          -  Patients with 24-hour urine protein&gt;2 g

          -  Patients with SGPT/ALT, SGOT/AST or total bilirubin continually increasing to more
             than twice the normal value(s)

          -  Patients with refractory infectious foci

          -  Patients with serious diarrhea or vomiting, active upper gastrointestinal ulcers or
             malabsorption

          -  Patients with serious heart or lung diseases or history of sugar tolerance abnormality
             or malignant tumors

          -  Patients allergic to tacrolimus or other basic medications

          -  Pregnant or lactating women

          -  Patients having participated in other clinical trials within the previous month

          -  Other patients who are considered by doctors unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/study.aspx?ID=202</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2016</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FK506</keyword>
  <keyword>Renal transplant recipients</keyword>
  <keyword>cyclosporin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

